Use of lasers for treating and reversing fibrosis
USRE50514E1 · kind E1 · reissue
Assignee
Inventors
Key dates
| Filing date | Dec 15, 2022 |
| Grant date | Aug 5, 2025 |
| Priority date | — |
| Expiry date | Dec 15, 2042 |
Classification
- Technology area (CPC —)General
Abstract
A method for treating a subject having a diseased or atrophic state of fibrotic tissue, kidney disease and associated nerve endings, or for promoting tissue regeneration in muscle tissue is accomplished through exposing the tissue with a laser light having a wavelength of about 400 nm to about 700 nm, or more preferably having a wavelength of about 405 nm, about 532 nm, about 635 nm, or a combination thereof. Subsequent to exposure, mesenchymal stem cells can be administered to the subject. After the administration of mesenchymal stem cells, the tissue is further exposed to laser light having a wavelength of about 400 nm to about 700 nm, or a laser light having a single wavelength of about 400 nm to about 700 nm. The mesenchymal cells can be interferon gamma activated.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.